Well, putting it bluntly, losing the chance for approval with Medsafe has put paid to the idea of a commercial phase 3 trial. The fate of the shareholders now rests on the company's ability to negotiate a favourable agreement with big pharma for a phase 3 trial...
There's no emoji here for my feelings on that.
Ann: Preliminary Final Report and 2019 Financial Statements, page-18
Add 1AI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.81M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.7¢ | $13.90K | 1.986M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 3764983 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 41489 | 1 |
View Market Depth
| Last trade - 10.57am 15/11/2024 (20 minute delay) ? |
| 1AI (ASX) Chart |